Saturday, March 23

**7:00 - 8:00**  
**BREAKFAST**

**8:00 - 8:15**  
**INTRODUCTION AND WELCOME**

**8:15 - 9:35**  
**CLINICAL UPDATES ON CAR T CELLS**  
**CHAIRS:** Jesus San Miguel and Yi Lin

- **8:15 - 8:25**  
  Ide-cel: latest data and ongoing trials  
  Paula Rodriguez-Otero

- **8:25 - 8:35**  
  Cilta-cel: latest data and ongoing trials  
  Jesus Berdeja

- **8:35 - 8:45**  
  Real world outcomes with CAR T cells for MM  
  Surbhi Sidana

- **8:45 - 8:55**  
  Update on GPRC5D CAR T cells  
  Omar Nadeem

- **8:55 - 9:35**  
  Discussion  
  Session faculty + Nizar Bahlis

**9:35 - 10:55**  
**CLINICAL UPDATES ON BISPECIFIC ABS/TCE’S**  
**CHAIRS:** Philippe Moreau and Hermann Einsele

- **9:35 - 9:45**  
  Teclistamab and Elranatamab: latest data and ongoing trials  
  Ajay Nooka

- **9:45 - 9:55**  
  Talquetamab and Forimtamig: latest data and ongoing trials  
  Adam Sperling

- **9:55 - 10:05**  
  The next bispecifics: Linvoseltamab, Alnuctamab, ABBV-383, Cevostamab  
  Hermann Einsele

- **10:05 - 10:15**  
  Combining bispecifics with monoclonal Abs, IMIDs, and each other  
  Yael Cohen

- **10:15 - 10:55**  
  Discussion  
  Session faculty + Emma Searle

**10:55 - 11:25**  
**BREAK**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:25 - 12:45</td>
<td><strong>HOW TO USE T CELL-DIRECTED THERAPIES TODAY AND IN THE FUTURE</strong></td>
</tr>
<tr>
<td><strong>CHAIRS:</strong></td>
<td><em>Kenneth Anderson and Marivi Mateos</em></td>
</tr>
<tr>
<td>11:25 - 11:35</td>
<td>What is optimal duration of therapy for bispecifics? Niels van de Donk</td>
</tr>
<tr>
<td>11:35 - 11:45</td>
<td>Sequencing CAR T cells and bispecifics for relapsed/refractory myeloma</td>
</tr>
<tr>
<td>11:45 - 11:55</td>
<td>How should we use T cell therapies in frontline and maintenance? Luciano Costa</td>
</tr>
<tr>
<td>11:55 - 12:05</td>
<td>T cell therapies for smoldering myeloma Irene Ghobrial</td>
</tr>
<tr>
<td>12:05 - 12:45</td>
<td>Discussion Session faculty + Noopur Raje</td>
</tr>
<tr>
<td>12:45 - 1:45</td>
<td><strong>LUNCH</strong></td>
</tr>
<tr>
<td>1:45 - 3:15</td>
<td><strong>NOVEL THERAPEUTIC APPROACHES AND TARGETS</strong></td>
</tr>
<tr>
<td><strong>CHAIRS:</strong></td>
<td><em>Sonja Zweegman and Eric Smith</em></td>
</tr>
<tr>
<td>1:45 - 1:55</td>
<td>Update on rapid manufacturing CAR T cell products Shambavi Richard</td>
</tr>
<tr>
<td>1:55 - 2:05</td>
<td>Dual antigen-targeted CAR T cells and trispecific antibodies Sham Mailankody</td>
</tr>
<tr>
<td>2:05 - 2:15</td>
<td>NK cell-based CAR and bispecific approaches Binod Dhakal</td>
</tr>
<tr>
<td>2:15 - 2:25</td>
<td>Targeting CD229 for myeloma therapy Tim Luetkens</td>
</tr>
<tr>
<td>2:25 - 2:35</td>
<td>Redirecting T cells against SLAMF7 Sophia Danhof</td>
</tr>
<tr>
<td>2:35 - 3:15</td>
<td>Discussion Session faculty + Sundar Jagannath</td>
</tr>
<tr>
<td>3:15 - 3:35</td>
<td><strong>BREAK</strong></td>
</tr>
<tr>
<td>3:35 - 5:00</td>
<td><strong>MANAGING TOXICITIES OF T CELL DIRECTED THERAPIES</strong></td>
</tr>
<tr>
<td><strong>CHAIR:</strong></td>
<td><em>Pieter Sonneveld and Melissa Alsina</em></td>
</tr>
<tr>
<td>3:35 - 3:45</td>
<td>Preventing infections after CAR T cell and bispecific Ab therapy Noopur Raje</td>
</tr>
<tr>
<td>3:45 - 3:55</td>
<td>Immune effector cell-associated hematotoxicity Kai Rejeski</td>
</tr>
<tr>
<td>3:55 - 4:05</td>
<td>Cardiac toxicity of CAR T cell therapy Sarju Ganatra</td>
</tr>
<tr>
<td>4:05 - 4:15</td>
<td>Neurotoxicity associated with BCMA-targeted T cell therapies Samir Parekh</td>
</tr>
<tr>
<td>4:15 - 5:00</td>
<td>Discussion Session faculty + Adam Cohen</td>
</tr>
</tbody>
</table>
### Sunday, March 24, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 - 8:00</td>
<td><strong>Breakfast</strong></td>
</tr>
<tr>
<td>8:00 - 8:05</td>
<td><strong>Welcome</strong></td>
</tr>
<tr>
<td>8:05 - 8:35</td>
<td><strong>Plenary Talk</strong></td>
</tr>
<tr>
<td></td>
<td>Stanley Riddell</td>
</tr>
<tr>
<td></td>
<td>Structure and function of novel bispecific chimeric T cell receptors</td>
</tr>
<tr>
<td>8:35 - 10:05</td>
<td><strong>Understanding Resistance to Immune Therapies</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Mehmet Samur and Marta Chesi</td>
</tr>
<tr>
<td>8:35 - 8:45</td>
<td>Mechanisms of antigen escape after T cell-redirecting therapies</td>
</tr>
<tr>
<td></td>
<td>Paola Neri</td>
</tr>
<tr>
<td>8:45 - 8:55</td>
<td>Using multi-omics to identify biomarkers of response to CAR T cell therapy</td>
</tr>
<tr>
<td></td>
<td>Maximilian Merz</td>
</tr>
<tr>
<td>8:55 - 9:05</td>
<td>Spatial profiling to interrogate the microenvironment</td>
</tr>
<tr>
<td></td>
<td>Madhav Dhodapkar</td>
</tr>
<tr>
<td>9:05 - 9:15</td>
<td>Using circulating tumor DNA to predict response or resistance</td>
</tr>
<tr>
<td></td>
<td>Hitomi Hosoya</td>
</tr>
<tr>
<td>9:15 - 9:25</td>
<td>Preclinical models to predict immune evasion</td>
</tr>
<tr>
<td></td>
<td>Jose Martinez-Climent</td>
</tr>
<tr>
<td>9:25 - 10:05</td>
<td>Discussion</td>
</tr>
<tr>
<td></td>
<td>Session faculty + Adam Cohen</td>
</tr>
<tr>
<td>10:05 - 10:30</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td><strong>Novel Approaches to Improve T Cell Therapies</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Ivan Borrello and Samir Parekh</td>
</tr>
<tr>
<td>10:30 - 10:40</td>
<td>Modulation of the microenvironment</td>
</tr>
<tr>
<td></td>
<td>Marc Raab</td>
</tr>
<tr>
<td>10:40 - 10:50</td>
<td>Disrupting Blimp-1 to enhance CAR T cell therapy</td>
</tr>
<tr>
<td></td>
<td>Carlos Fernandez de Larrea</td>
</tr>
<tr>
<td>10:50 - 11:00</td>
<td>Novel targets and technologies for CAR-T in MM</td>
</tr>
<tr>
<td></td>
<td>Michael Hudecek</td>
</tr>
<tr>
<td>11:00 - 11:10</td>
<td>In situ PEGylation to reduce CAR T cell-associated toxicities</td>
</tr>
<tr>
<td></td>
<td>Michael Mitchell</td>
</tr>
<tr>
<td>11:10 - 11:20</td>
<td>Clutch control: changing speed and direction of CAR T cell therapies</td>
</tr>
<tr>
<td></td>
<td>Carl Novina</td>
</tr>
<tr>
<td>11:20 - 12:00</td>
<td>Discussion</td>
</tr>
<tr>
<td></td>
<td>Session faculty + Nizar Bahlis</td>
</tr>
<tr>
<td>12:00 - 1:00</td>
<td><strong>Lunch</strong></td>
</tr>
<tr>
<td>1:00 - 2:00</td>
<td><strong>Current Questions in Immune Effector Cell Therapies for MM</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Shaji Kumar and Kwee Yong</td>
</tr>
<tr>
<td>1:00 - 1:10</td>
<td>Should we profile T cell fitness prior to T cell-redirecting therapy?</td>
</tr>
<tr>
<td></td>
<td>Bruno Paiva</td>
</tr>
<tr>
<td>1:10-1:20</td>
<td>Should we profile antigen expression/mutation status prior to T cell-redirecting therapy?</td>
</tr>
<tr>
<td></td>
<td>Leo Rasche</td>
</tr>
<tr>
<td>1:20-1:30</td>
<td>Can vaccines or novel checkpoint inhibitors enhance response to CARTs or BsAbs?</td>
</tr>
<tr>
<td></td>
<td>David Avigan</td>
</tr>
<tr>
<td>1:30-2:00</td>
<td>Discussion</td>
</tr>
<tr>
<td></td>
<td>Session faculty + Marc Raab</td>
</tr>
</tbody>
</table>
WORKSHOP ON EXPANDING ACCESS TO T CELL THERAPIES

CHAIRS: Nikhil Munshi and Amrita Krishnan

2:00-2:10 Improving clinical trial enrollment of underrepresented populations
Monique Hartley-Brown

2:10-2:20 Improving real-world access to T cell therapies in the US
Ben Derman

2:20-2:30 Challenges associated with T cell therapies in South America
Vania Hungria

2:30-3:15 Discussion
Session faculty + Kenneth Anderson, Sundar Jagannath, Philippe Moreau

3:15-3:30 CONCLUSION AND WRAP-UP

Thank you to our sponsors

TITANIUM
Bristol Myers Squibb
Johnson&Johnson
sanofi

PLATINUM
Kite
A GILEAD Company
ARCELIX
Pfizer

GOLD
abbvie

SILVER
Genentech
A Member of the Roche Group